EP
FULC icon

Eversept Partners’s Fulcrum Therapeutics FULC Stock Holding History

Eversept Partners’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-152,965
Closed -$948K – 70
2024
Q2 		$948K Buy
+152,965
New +$1.16M 0.06% 69

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eversept Partners's FULC Position: Q3 2024 in Review

Eversept Partners sold out of Fulcrum Therapeutics (FULC) in Q3 2024, closing a stake of 152,965 shares — an estimated $948K sold.

Eversept Partners first reported a position in FULC in Q2 2024 and held it in 1 quarter. The position peaked at $948K in Q2 2024. 130 funds tracked by Wall St. Rank hold FULC as of Q3 2024.

  • Eversept Partners reported no remaining Fulcrum Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Eversept Partners sold 152,965 Fulcrum Therapeutics shares in Q3 2024, an estimated $948K.
  • Eversept Partners first reported a position in Fulcrum Therapeutics in Q2 2024 and held it in 1 quarter.
  • Eversept Partners's Fulcrum Therapeutics position peaked at $948K in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.